Institute of Pharmaceutical Research, GLA University, NH-2 Mathura Delhi Road P.O- Chaumuhan, Mathura, 281406, U.P, India.
College of Pharmacy, BSA College of Engineering and Technology, Mathura, India.
Daru. 2024 Dec;32(2):947-965. doi: 10.1007/s40199-024-00543-w. Epub 2024 Oct 3.
In the recent years, in-situ hydrogel based on gellan gum has been investigated for delivery of various drug molecules particularly to treat neurological disorders via intranasal route. The major objective of the present manuscript is to review the recent research studies exploring gellan gum as ionic triggered in-situ gel for intranasal administration to enhance absorption of drugs and to increase their therapeutic efficacy.
This review include literature from 1982 to 2023 and were collected from various scientific electronic databases like Scopus, PubMed and Google Scholar to review source, chemistry, ionotropic gelation mechanism, and recent research studies for gellan gum based in-situ hydrogel for intransasl administration.Keywords such as gellan gum, in-situ hydrogel, intranasal administration and brain targeting were used to search literature. The present review included the research studies which explored gellan gum based in-situ gel for intranasal drug delivery.
The findings have shown enhanced biavailability of various drugs upon intranasal administration using gellan-gum based in-situ hydrogel.Moreover, the review indicated that intranasal administration of in-situ hydrogel facilitate to overcome blood brain barrier effectively. Hence, significantly higher drug concentration was found to be achieved in brain tissues upon intranasal administration than that of other routes like oral and intravenous.
The present work conducted a comprehensive review for gellan gum based in-situ hydrogel particularly for intransal administration to overcome BBB. The study concluded that gellan gum based in-situ hydrogel could be potential promising delivery system for intranasal administration to improve bioavailability and efficacy of drugs specifically to treat neurological disorders.
近年来,基于结冷胶的原位凝胶已被研究用于输送各种药物分子,特别是通过鼻内途径治疗神经障碍。本手稿的主要目的是综述最近探索结冷胶作为离子触发原位凝胶用于鼻内给药以增强药物吸收并提高其治疗效果的研究。
本综述包括 1982 年至 2023 年的文献,并从 Scopus、PubMed 和 Google Scholar 等各种科学电子数据库中收集,以综述来源、化学、离子凝胶化机制以及基于结冷胶的原位水凝胶用于经鼻给药的最新研究。使用了诸如结冷胶、原位凝胶、经鼻给药和脑靶向等关键词来搜索文献。本综述包括探索基于结冷胶的原位凝胶用于经鼻给药的研究。
研究结果表明,经鼻给予结冷胶基原位凝胶可提高各种药物的生物利用度。此外,综述表明,原位凝胶的经鼻给药有助于有效地克服血脑屏障。因此,与其他途径(如口服和静脉内)相比,经鼻给予原位凝胶时在脑组织中发现的药物浓度显著更高。
本工作对结冷胶基原位凝胶进行了全面综述,特别是为克服 BBB 而进行的经鼻给药。研究得出结论,结冷胶基原位凝胶可为提高生物利用度和疗效的经鼻给药提供有前途的给药系统,特别是用于治疗神经障碍。